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Purpose: Distinguishing radiation necrosis (RN) from recurrent tumor remains a vexing
clinical problem with important health-care consequences for neuro-oncology patients.
Here, mouse models of pure tumor, pure RN, and admixed RN/tumor are employed to
evaluate hydrogen ( 1 H) and deuterium ( 2 H) magnetic resonance methods for
distinguishing RN vs. tumor. Furthermore, proof-of-principle, range-ﬁnding deuterium
(2H) metabolic magnetic resonance is employed to assess glycolytic signatures
distinguishing RN vs. tumor.
Materials and Methods: A pipeline of common quantitative 1H MRI contrasts, including
an improved magnetization transfer ratio (MTR) sequence, and 2H magnetic resonance
spectroscopy (MRS) following administration of 2H-labeled glucose, was applied to
C57BL/6 mouse models of the following: (i) late time-to-onset RN, occurring 4–5
weeks post focal 50-Gy (50% isodose) Gamma Knife irradiation to the left cerebral
hemisphere, (ii) glioblastoma, growing ~18–24 days post implantation of 50,000 mouse
GL261 tumor cells into the left cerebral hemisphere, and (iii) mixed model, with GL261
tumor growing within a region of radiation necrosis (1H MRI only). Control C57BL/6 mice
were also examined by 2H metabolic magnetic resonance.
Results: Differences in quantitative 1H MRI parametric values of R1, R2, ADC, and MTR
comparing pure tumor vs. pure RN were all highly statistically signiﬁcant. Differences in
these parameter values and DCEAUC for tumor vs. RN in the mixed model (tumor growing
in an RN background) are also all signiﬁcant, demonstrating that these contrasts—in
particular, MTR—can effectively distinguish tumor vs. RN. Additionally, quantitative 2H
MRS showed a highly statistically signiﬁcant dominance of aerobic glycolysis (glucose ➔
lactate; fermentation, Warburg effect) in the tumor vs. oxidative respiration (glucose ➔
TCA cycle) in the RN and control brain.
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Conclusions: These ﬁndings, employing a pipeline of quantitative 1H MRI contrasts and
2
H MRS following administration of 2H-labeled glucose, suggest a pathway for
substantially improving the discrimination of tumor vs. RN in the clinic.
Keywords: MRI, tumor, radiation necrosis, metabolic imaging, deuterium

cells implanted in Balb/c mice (11) and ii) GL261 cells implanted
in C57BL/6 mice (12).
As noted above, while distinguishing radiation necrosis from
recurrent tumors remains a vexing clinical problem with
important health-care consequences for neuro-oncology
patients, there are obvious research limitations to the
recruitment of relevant clinical populations for development
and validation of new imaging biomarkers. A major challenge
is the lack of quantitative correlative histology, which is not
readily available in most patients and is, at best, highly localized
tissue obtained using invasive surgical procedures (re limited
biopsy or craniotomy with surgical resection). Our mouse
models offer speciﬁc platforms with stratiﬁed populations of
pure RN, pure tumor, and tumor growing in a RN background,
the “mixed” model. Further, hematoxylin and eosin (H&E)
histology provides a “gold standard” conﬁrmation of lesion
location/boundary and, in the mixed model (RN invaded with
tumor cells), lesion identity. These animal models allow us to test
the robust, standard-of-care imaging capability of MR
biomarkers, whether structural, functional, or metabolic. The
goals of this study were to employ our mouse models of pure
tumor, pure RN, and admixed RN/tumor to evaluate a pipeline
of common quantitative hydrogen (1H) MR contrasts, including
magnetization transfer ratio (MTR), for distinguishing RN vs.
tumor. The MTR contrast—tumor vs. RN—was improved over
previous work from this laboratory (16) by the selection of pulse
sequence parameters that minimized direct saturation of the 1H
water signal. Further, proof-of-principle, range-ﬁnding
deuterium (2H) metabolic magnetic resonance was employed
following administration of 2 H-labeled glucose to assess
glycolytic signatures, distinguishing RN vs. tumor.

INTRODUCTION
Most neuro-oncology patients, including those with primary or
secondary malignant brain tumors, are treated with radiation as
an early therapeutic modality. These patients are at risk of
developing delayed adverse effects related to the prior
radiation, including late time-to-onset radiation necrosis (RN).
Additionally, patients are at risk of developing recurrent cancer,
most often within regions of the previously irradiated brain.
Changes in post-therapy surveillance magnetic resonance
imaging (MRI) features due to RN alone or recurrent tumor
admixed with RN often present overlapping RN vs. tumor
signatures. Thus, post-treatment MRI may be indeterminate
and unable to accurately distinguish changes dominated by RN
from recurrent tumors growing within an area of RN. While MRI
multi-parametric analysis, including diffusion-weighted and
dynamic susceptibility contrast (DSC) MRI, has improved
differentiation of RN from mixed recurrent tumor/RN,
standard, quantitative MR metrics for distinguishing these
pathologies are still lacking (1–4). Similar indeterminacy is
evident from 1 H MRS studies (5–8) in which various
endogenous metabolite metrics show 70–80% sensitivity and
speciﬁcity in distinguishing RN from recurrent tumors.
Thus, the problem of accurately identifying tumor recurrence
within a background of RN distinct from pure RN remains an
important unmet clinical need in the management of neurooncology patients. Identiﬁcation of imaging biomarkers capable
of accurately distinguishing lesions dominated by RN from
recurrent tumors admixed within regions of RN would be a
major clinical advance, allowing oncologists to offer the best
available treatment options in a timely fashion.
For many years, we have studied the late effects of radiation
on normal brain tissue, having developed and characterized
extensively a mouse model of late time-to-onset RN (9–18).
Recently, we have described the late persisting impact of previous
radiation on subsequent tumor growth (11) and on the
responsiveness of tumors to immunotherapy (12). Of late, we
have employed this radiation-biology platform to develop a
novel mouse model that recapitulates many of the clinical
features of recurrent malignant gliomas. In this murine model,
tumor cells that have not been exposed to radiation are
implanted within the ipsilateral hemisphere ~3.5–4 weeks after
Gamma Knife (GK) irradiation of 30 or 50 Gy. The morphology
of lesions in this post-irradiation implantation model is
strikingly distinct from lesions resulting from gliomas
implanted into non-irradiated brains. These ﬁndings are robust
and have been observed in two syngeneic orthotopic murine
malignant glioma models in two different mouse strains: i) DBT
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MATERIALS AND METHODS
Mouse Models
General
All experiments were performed in accordance with the
guidelines of Washington University’s Institutional Animal
Care and Use Committee and were approved by that
committee. Seven-to eight-week-old female C57BL/6 mice
(Envigo Laboratories; Indianapolis, IN), housed four or ﬁve per
cage in a light- and temperature-controlled facility, were used in
this study. Three mouse models were studied: i) pure RN, ii) pure
GL261 tumor, and iii) a “mixed” model, with tumor growing in
RN. Separate cohorts of mice were employed in 1H MRI and 2H
MR spectroscopy experiments.

2

May 2022 | Volume 12 | Article 885480

Ge et al.

Distinguishing Tumor vs. Radiation Necrosis

(CA): 100 µl 50% (V/V) Dotarem ® (Guerbet LLC USA,
Princeton, NJ) in saline.

Gamma Knife Irradiation
All mouse-brain irradiations were performed using the Leksell
GK Perfexion™ (Elekta, Stockholm, Sweden), a device used for
stereotactic radiosurgery of patients. Mice were anesthetized with
a mixture of ketamine (25 mg/kg) and xylazine (5 mg/kg),
injected intraperitoneally (IP), and restrained on a custombuilt platform mounted to the GK’s stereotactic frame. Singlefraction, 50-Gy radiation doses (50% isodose), generated using
the GK’s 4-mm collimator, were focused on the left cortex at a
site ~2 mm posterior to the bregma. Irradiated mice developed
RN beginning approximately four weeks post-irradiation, as
described previously (15).

1

H MRI Pipeline

A multi-contrast pipeline (Figure 1) was applied to models of pure
RN, pure tumor, and tumor growing in RN. The parameters
associated with all of the pipeline pulse sequences are listed below.
Unless otherwise noted, matrix size was 64 × 64, ﬁeld of view
(FOV) 16 × 16 mm2, and 21 slices with a slice thickness of 0.5 mm.

T2-Weighted Imaging
T2W images were acquired with a 2D fast spin-echo multi-slice
(FSEMS) sequence: echo train length (ETL) 4, Kzero 4, TR 2 s,
effective TE 52 ms; matrix size 128 × 128, 4 averages.

Tumor Implantation
For tumor implantation, mice were anesthetized with isoﬂurane
and secured in a stereotactic head holder. Murine GL261
glioblastoma cells were implanted (~50,000 cells suspended in
10 ml per mouse) over 3 min at a site coincident with the focus of
the GK radiation, 2 mm posterior and 3 mm to the left of
bregma, and 2 mm below the cortical surface. For the pure tumor
model, GL261 cells were implanted into non-irradiated mice. In
the mixed model, GL261 cells were implanted into the irradiated
hemisphere four weeks post irradiation.
1

T1-Weighted Imaging
T1W images were acquired with a 2D spin-echo multi-slice
(SEMS) sequence: TR 0.4 s, effective TE 11 ms, matrix size 128 ×
128, 4 averages.

R1 Mapping
R1 maps were acquired using a 2D gradient-echo multi-slice
(GEMS) sequence: TR 0.1 s, TE 1.6 ms; ﬂip angles of 5, 10, 15, 30,
50, and 70 degrees; 4 averages.

H MRI

R2 Mapping

Experimental Setup

R2 maps were acquired with a 2D multi-echo multi-slice
(MEMS) sequence: TR 6.0 s, echo spacing 11 ms in 16 steps
(11 ms to 176 ms); 1 average.

The 1H MRI experiments employed a 4.7-T small-animal MR
scanner with an Agilent/Varian (Santa Clara, CA) DirectDrive™
console and an Oxford Instruments (Oxford, United Kingdom)
horizontal superconducting magnet. Data were collected with a
laboratory-built, actively-decoupled transmit and receive RF coil
pair: a 7.5-cm ID volume transmitter coil and a 1.5-cm OD
surface receiver coil. Mice were placed on a warm-water pad and
anesthetized with isoﬂurane/O 2 (1.2–1.5% isoﬂurane)
throughout the experiment. During MRI procedures, a Small
Animal Instruments (SAI, Stony Brook, NY) monitoring and
gating unit was used to monitor mouse respiratory rate, ~60
breaths/min, and body temperature, 37 ± 0.5 °C (rectal probe).
Before placing each mouse into the magnet, a tail-vein catheter
was inserted for subsequent injection of Gd-based contrast agent

Diffusion Weighted Imaging
Diffusion-sensitive images (re ADC) were acquired with a 2D
FSEMS sequence: ETL 2, Kzero 1, TR 1.5 s, effective TE 30 ms,
the duration of diffusion sensitizing gradient lobe (d) 3 ms, time
between diffusion sensitizing gradient lobes (D) 18 ms; 6direction diffusion encoding (19), max b-value 1,000 s/mm2,
2 averages.

Magnetization Transfer
Magnetization transfer data were acquired using a 2D FSEMS
sequence with the RF irradiation used to induce magnetization

FIGURE 1 | Schematic of the 1H MRI data acquisition pipeline.
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transfer turned either on or off: ETL 8, Kzero 1, TR 2.0 s, effective
TE 6.5 ms, and 8 averages following 4 full dummy scans to
establish a steady state. Magnetization transfer RF irradiation:
10-ms Gaussian-shaped pulses (ﬂip angle 900 degrees) offset
2,000 Hz (10 ppm) from the water resonance. The parameter
values were chosen to minimize the direct saturation of the 1H
water signal.

Single Voxel Spectroscopy With Phantom
In anticipation of using the localized SPin-ECho full-Intensity
Acquired Localized (SPECIAL) spectroscopy sequence (21) for
in vivo studies, one-dimensional slice proﬁles in the x-, y-, and zdirections were collected with SPECIAL. Hyperbolic secant 180°
and 90° adiabatic pulses were employed in concert with standard
outer volume suppression (OVS) (22). The phantom consisted of
a 10% D2O solution contained in a 5-ml plastic syringe (~1.2mm ID). SPECIAL parameters include TR 450 ms, TE 4.27 ms,
64 averages, 512 complex data points, 2,000-Hz acquisition
bandwidth, voxel size 4 × 4 × 4 mm3, and 10-mm OVS bands
employing 90° hypersecant pulses adjacent to the edges of the
single voxel on all sides.

Dynamic Contrast Enhancement (DCE)
In concert with bolus tail-vein administration of CA, DCE data
were acquired with a GEMS sequence: 15 slices (center slice coregistered to the center slice of the 21-slice array), TR 47 ms, TE
1.6 ms, 1 average, ﬂip angle 30°, and 300 time frames with 3-s
time resolution.
2

Single Voxel Spectroscopy In Vivo
For in vivo experiments, the acquisition of anatomic 1H MRI was
followed by 1H B0 map-based gradient shimming, resulting in a
typical 1H water linewidth of ~40 Hz across a 3 × 3 × 3 mm3 to
4 × 4 × 4 mm3 voxel (27–64 µl). In tumor-bearing and RN mice,
anatomic images were acquired after IP injection of a Gd-based
T1 contrast agent. The voxel position of the region of interest was
selected by analyzing a 1H multi-slice T1W image collected with
a Fast Spin-Echo (FSE) sequence: TR 500 ms, TE 9.5 ms, FOV
16 × 16 mm2, 16 averages, slice thickness 1 mm, and matrix size
128 × 128. Localized 2H spectra were then acquired from a voxel
positioned around the lesion region using the SPECIAL sequence
with standard OVS (22) employing 90° hypersecant pulses. The
OVS bands were 10-mm wide, and the suppression volume was
adjacent to the edges of the single voxel on all sides. As 2H T2 is
limited for tissue water (~20 ms) and glucose (~30 ms) (23), TE
is short (4.27 ms), a desirable attribute of the SPECIAL sequence.
2
H MRS datasets were acquired in nominal ten-minute time
blocks (10.5 min). Acquisition parameters include TR 450 ms,
TE 4.27 ms, 1,400 averages, 1,024 complex data points, 1,500-Hz
acquisition bandwidth, voxel size 3 × 3 × 3 mm3 to 4 × 4 × 4
mm3, hyperbolic secant 180° and 90° adiabatic pulses.

H MR Spectroscopy

Experimental Setup
The deuterium metabolic magnetic resonance experiments
were designed as proof-of-principle, range-ﬁnding studies to
discern the ability of the technique to discriminate pure tumor
from pure RN. For these initial 2H experiments, we employed
single-voxel spectroscopy (SPECIAL) performed at 11.74 T with
an Agilent/Varian DirectDrive™ console and an Agilent/
Magnex (Yarnton, Oxford, United Kingdom) horizontal
superconducting magnet. 1H images, used for ﬁeld shimming,
planning, and anatomic registration of the 2 H data,
were collected with a 50-mm ID volume coil tuned to 499.3
MHz. 2H RF transmission and reception employ a one-turn
21-mm ID 2H surface coil tuned to 76.65 MHz. Anesthesia
and physiologic monitoring were as described above for 1H MR
imaging experiments.

Semiheavy Water Natural Abundance
Quantitative 2H MRS beneﬁts from knowledge of the local
(regional) natural abundance of 2H in the water supply, as this
will also be the natural-abundance 2H concentration in tissue
water (vide infra), which provides a convenient internal
concentration reference. Titration experiments using the method
of standard addition were employed to establish/conﬁrm the 2H
natural abundance in the St. Louis region water supply (20). This
measurement of 2H natural abundance is directly relevant to our
in vivo MRS experiments since mice in our animal facility are
routinely provided local tap water to drink. Deuterium oxide
(“heavy water”; D2O, 99.9%; D = 2H; Sigma Aldrich Co.; St.
Louis, MO) was mixed with tap water to produce individual
samples of increasing 2H concentration. Because of rapid
chemical exchange, 2H exists in these samples as 1HO2H
(= HOD; “semiheavy water”), and 2H content was titrated in
terms of DHOD relative to tap water. Here, DHOD represents 2H
content above natural-abundance levels found in local tap water.
Five 2H-enriched samples, having DHOD = 36, 72, 108, 144, and
180 mM, respectively, were prepared. Pulse-and-collect 2H MR
spectra were acquired under quantitative conditions: 80 µs 90°
rectangular RF pulse, TR 3,000 ms, 64 averages, 1,024 complex
data points, and 1,500-Hz acquisition bandwidth.

Frontiers in Oncology | www.frontiersin.org

2

H MRS Metabolic Monitoring

Single-voxel spectroscopy data were acquired as described above
to monitor the metabolism of [6,6-2H2]glucose (Glc) for tumorbearing, RN, and control mice (n = 4, each). Glc was injected at a
dose of ~2 g/kg body weight. Dosage was not adjusted for animal
weights, which varied by less than 5% across the twelve mice
(mean body weight = 19.5 g; SD = 0.76 g). Before 2H MRS data
acquisition, voxel-speciﬁc 1H MR magnetic-ﬁeld shimming
yielded water 1H linewidths of ~40–45 Hz (~0.08–0.09 ppm).
SPECIAL 2H MRS data were acquired in repeated 10-min signalaveraged blocks from voxels positioned around the tumor or RN
lesion. Two initial 10-min signal blocks were acquired before the
administration of Glc to quantify the natural abundance of HOD
signal, a convenient internal concentration reference. During the
third 10-min acquisition block, 36-mg (2 × 10−4 mole) of Glc in
200 µl saline (180 mg/ml) was administered via the tail vein, and
this same Glc solution was slowly infused (130 µl/h) during eight
subsequent 10-min acquisition blocks. The repetitive 10-min
acquisitions enabled time-course monitoring of the conversion
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of Glc to, ideally, [3,3-2H2]-labeled lactate (Lac) and [4,4-2H2]labeled glutamine and glutamate, detected as the content sum of
the two metabolites (Glx) (23). Based on recent 2H label-loss data
(24), the Lac resonance was assigned a stoichiometry of 1.7 (15%
loss of label) and the Glx resonance a stoichiometry of 1.2 (40%
loss of label). The concentration ratio Glx : Lac provides a
measure of the oxidative (TCA cycle) vs. glycolytic (Warburg
effect) pathway ﬂux of administered Glc.

acquisition, accounting for the diffusion weighting of the
imaging gradients:
S(b) = S(b = 0) × exp(−b × D),
in which b is formally the b-matrix for each diffusionweighted MR image.
[3]
• MTR maps were calculated via the normalized ratio of signal
difference from experiments with MT RF irradiation (ON)
and without MT RF irradiation (OFF):
MTR = 100% × (OFF − ON)/OFF.
[4]

Hematoxylin and Eosin (H&E) Histology
Mice were sacriﬁced and their brains were immediately removed
from the skulls and immersed in 10% formalin for 24 h. The
brains were then transferred to a 20% alcohol solution. A 3-mm
thick transaxial block, centered at the irradiation site (~3 mm
behind the bregma), was obtained from each brain. The blocks
were then processed through graded alcohols and embedded in
parafﬁn. All parafﬁn-ﬁxed blocks were sectioned from the center
at a thickness of ﬁve microns. Tissue sections were stained with
H&E according to standard protocols.

• The area under the DCE time-course curve (DCEAUC) was
calculated following contrast-agent injection. To account for
baseline (pre-administration of contrast agent) signal
variations between subjects, the signal at each time point
was expressed as the fractional enhancement in voxel
intensity relative to the pre-contrast period. The signal was
further normalized by the maximum fractional enhancement
in the early time frames (nos. 31–120) of the temporalis and
masseter muscles to account for potential modest variations
in contrast-agent delivery. AUC was expressed on a per-unittime (s) basis by dividing the sum of the normalized signal
over the post-injection time frames by 810 (3 s/frame × 270
post-injection frames).

Data Analysis and Statistics
1

H MRI Pipeline Analysis Strategy

All images were processed with an “un-ringing” algorithm (25)
and a Gaussian ﬁlter (s = 0.75). The R1, R2, and ADC parametric
maps were computed on a voxel-wise basis with the Bayesian
Toolbox (26), a data modeling software package based upon the
precepts of Bayesian probability theory. The voxel-wise maps of
MTR and DCE AUC were calculated in MATLAB (The
Mathworks, Natick, MA). The signal models/equations used in
these analyses are summarized below.
For each mouse, lesions were segmented using ITK-SNAP
(www.itksnap.org) (27). Regions of interest (ROI) were drawn
manually based principally upon MTR and post-contrast R1
parametric maps, supported by central-lesion H&E-stained
tissue slice(s). Individual ROIs were drawn on each image slice
to faithfully outline regions dominated by tumor/lesion contrasts.
The ROIs were drawn conservatively to avoid ventricles and
partial volume effects. For RN, post-contrast R1 was the primary
contrast used for segmentation; for tumors, MTR and postcontrast R1 were used iteratively for segmentation.

2

H MRS Analysis

2

H FID’s were analyzed via Bayesian time-domain signal
modeling as sums of exponentially decaying sinusoids using the
Bayesian Toolbox (26). Bayesian modeling provides probability
density functions (PDFs) for each resonance frequency, decay-rate
constant (R2*), and amplitude. Estimates of these parameter
values were assigned as the means of each parameter’s PDF;
uncertainties were assigned as the standard deviation of that
parameter’s PDF. For each resonance, the frequency and R2*
were estimated as common values across a given time course.
Individual resonance amplitudes were estimated for each time
frame. The 2H resonance amplitudes for Glc, Lac, and Glx,
proportional to metabolite concentrations, were corrected for
labeling stoichiometry (vide supra), and relaxation effects using
published T1 and T2 values (23). Amplitudes of the modeled water
(HOD) and metabolite 2H resonances were converted to
concentrations (mmoles/liter of tissue water) using the
amplitude of the natural-abundance HOD signal acquired before
administration of Glc as an internal reference.

MR Signal Models
Data were analyzed using standard signal models, as
described below.
• The R1 maps were calculated via a variable ﬂip angle (q)
experiment
S(q) = S(Boltzmann) × (1 − exp(−TR × R1)) × sin(q)/(1 − exp
(−TR × R1) × cos(q)).
[1]

Statistical Analysis
Differences in measured 1H MR parameters (e.g., R1, R2, ADC,
MTR, DCEAUC ) between pure tumor and pure RN, and
differences between different models (e.g., tumor in the mixed
lesion model vs. pure tumor; necrosis in the mixed lesion model vs.
pure necrosis) were compared using two-tailed t-tests. Parameter
values for tumor and necrosis within the mixed lesion model were
compared using a paired t-test. The resultant p-values were
adjusted by a step-down Bonferroni adjustment for multiple
comparisons. Time-course 2H spectroscopy data were analyzed
using two-way ANOVA for repeated measurement, followed by

• The R2 maps were calculated via a multi-spin-echo (i.e.,
multi-TE) experiment:
S(TE) = S(TE = 0) × exp(−TE × R2) + Constant.
[2]
• ADC maps—1/3 × Trace of the diffusion tensor D (ADC =
1/3 × Trace(D))—were calculated from diffusion-weighted
MR images via six diffusion-encoding b-vectors and a b = 0

Frontiers in Oncology | www.frontiersin.org
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in this group compared to mice implanted with tumor alone (i.e.,
without RN in the background).

post-hoc comparison of the least squares means across groups
(control vs. tumor-bearing vs. necrosis). All analyses were
performed using SAS 9.4 (SAS Institutes, Cary, NC). Statistical
signiﬁcance was deﬁned as a two-tailed p-value of <0.05.

1

H MRI Pipeline

The 1H MR pipeline (Figure 1) was applied to study three
different cohorts of mice—pure RN, pure tumor, and mixed RN/
tumor—with the goal of identifying individual imaging contrasts,
or combinations thereof, for distinguishing pure RN from RN
admixed with tumor. Representative post-contrast T1W and
T2W images of the brains of mice in each of these cohorts are
shown in Figure 3. Lesions are clearly visible in each of these
images, and total lesion volumes (RN, tumor, mixed tumor +
RN) were measured quantitatively by inspection of T1W and
T2W images and manual segmentation. However, anatomic
images alone are not able to reliably distinguish between RN
and tumor. To address this challenge, we computed parametric
maps of R1, R2, ADC, DCEAUC, and MTR. Representative
parametric maps illustrating typical data quality are shown in
Figure 4. Yellow circles/ovals drawn on these maps guide the eye
to the locations of lesions. Regions of interest corresponding to
lesions observed in T1W and T2W images were drawn manually
on each parametric map. Table 1 summarizes measurements of
R1, R2, ADC, DCEAUC, and MTR in pure tumor, pure RN, and
the mixed tumor/RN model. For each member of the mixed
model cohort, regions of conﬁrmed tumor and of RN were

RESULTS
The Mixed Tumor/Radiation Necrosis
(RN) Model
As noted earlier, three preclinical models, namely, orthotopically
implanted tumor, pure RN, and the mixed tumor/RN model, are
well established in our lab (9–18). In the mixed tumor/RN model,
GL261 tumor cells were implanted into the previously irradiated
brain four weeks post-irradiation. Conventional H&E staining of
the tumor in the non-irradiated brain, Figure 2 (top), shows a
relatively solid malignant glioma in the brain. High-grade gliomas
are characterized by dense cellularity, signiﬁcant pleomorphism,
and frequent mitoses. By contrast, in the mixed model, Figure 2
(bottom), malignant glioma cells are admixed within a region of
RN; the latter is characterized by areas of rarefaction, gliosis, and
vasculopathy obvious within the brain parenchyma surrounding
the implanted malignant tumor cells. Also notable is the presence
of necrosis within the tumor itself, which was much more frequent

FIGURE 2 | Conventional H&E staining of: (top) GL261 tumor growing in non-irradiated mouse brain (C57BL/6); (bottom) mixed model, with tumor growing within a
region of radiation necrosis. Scale bars on the whole-mount images (left) represent a length of 1 mm; the expanded images (right) are at a magniﬁcation factor of 10×.
Black arrows indicate areas of hemorrhage and necrosis (bottom, left) and vasculopathic changes (bottom, right).
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FIGURE 3 | (top) T1-weighted and (bottom) T2-weighted images, both acquired post contrast, of: (left) pure tumor; (middle) pure RN; and (right) the mixed model.

confounded by a substantial MT effect. Compared to singleslice, “gold standard” inversion recovery (IR) R1 mapping,
having minimal MT effect, the lesion VFA R1 values were 1.8×
greater than the corresponding IR R1 values (data not shown)].
The quantitative MR parametric values of R1, R2, ADC, and
MTR comparing tumor alone (n = 9) vs. RN alone (n = 9) are all

identiﬁed by histology, allowing regions of interest for tumor and
for RN to be drawn separately on the various parametric maps.
Thus, separate mean parameter values (± SD) for tumor and for
RN in the mixed model are reported in the table (lines 3 and 4,
respectively). [Note: While the variable ﬂip angle (VFA) R1
mapping method used clinically is time-efﬁcient, results are

FIGURE 4 | Parametric maps, derived from the 1H MRI pipeline of (left) pure tumor; (middle) pure radiation necrosis, and (right) mixed model. From top to bottom,
maps are shown of R1 (= 1/T1), R2 (= 1/T2), apparent diffusion coefﬁcient (ADC), DCE area under the curve (AUC), and magnetization transfer ratio (MTR). Yellow
circles/ovals guide the eye to the locations of lesions in each of these maps.

Frontiers in Oncology | www.frontiersin.org

7

May 2022 | Volume 12 | Article 885480

Ge et al.

Distinguishing Tumor vs. Radiation Necrosis

TABLE 1 | Mean MR Parameter Values.
R1 (SD) [s−1]
Tumor
RN
Tumor in Mixed
RN in Mixed

1.08
1.26
1.05
1.28

(0.11)
(0.09)
(0.06)
(0.08)

R2 (SD) [s−1]

ADC (SD) [mm2/ms]

14.9 (0.87)
17.6 (0.72)
14.2 (0.59)
17.7 (1.16)

0.833
0.736
0.872
0.704

highly statistically signiﬁcant (Table 2). Differences in these
parameter values, as well as DCEAUC, for tumor vs. RN in the
mixed model are also all signiﬁcant, demonstrating that these
contrasts can all effectively distinguish tumor from RN in the
mixed model. Readouts from the pure models (tumor alone, RN
alone) were largely similar (i.e., not statistically different)
compared to regions of the same lesion in the mixed model.
Only tumor MTR and DCEAUC values showed statistically
signiﬁcant differences comparing pure tumor vs. mixed-lesion
tumor (p = 0.013 and p= 0.035, respectively), and these were
modest compared to differences in MTR and DCEAUC metrics
between mixed-lesion tumor vs. mixed-lesion RN. Thus, the pure
lesion models provide substantial predictive insight into MRI
parameter readouts that are characteristic of tumor vs. RN
regions in the mixed lesion. An additional feature of these
mouse models is that cortex in the contralateral brainhemisphere provides intra- and inter-subject non-lesion
control tissue. Indeed, comparing each 1H MRI parameter for
the contralateral cortex across the three lesion model cohorts
(tumor alone, RN alone, and mixed), none showed statistically
signiﬁcant differences, except for MTR comparing contralateral
cortex in the mixed lesion vs. RN alone models (p = 0.01), and
the difference was small (5%).
Of particular note is our observation that MTR cleanly
discriminates between tumors and RN. Distinct from an earlier
MTR protocol reported by our lab (14), MTR pulse sequence
parameters were chosen to avoid substantial direct T1 weighting
(TR = 2 s) and to minimize direct saturation of the water
resonance (~4%). The ability of MTR contrast to distinguish
tumor vs. RN in the mixed lesions is illustrated in Figure 5. Here,
post-contrast T1W images, MTR parametric maps, and H&E
histology are shown for pure tumor, pure RN, and the mixed
model. In this ﬁgure, red contours outline ROIs of RN; yellow
contours outline ROIs of the tumor. The location of the tumor
and/or RN in the T1W images and MTR parametric maps is
conﬁrmed by histology. Consistent with the numbers reported in
Table 1, tumors appear dark on maps of MTR, while RN lesions
are indistinguishable from the contralateral cortex. Further,
MTR of the pure RN lesion is not statistically different from

AUC (SD) [au]

(0.053)
(0.052)
(0.042)
(0.049)

0.916
0.784
1.22
0.658

(0.256)
(0.247)
(0.37)
(0.110)

MTR (SD) [%]
24.1
30.2
22.2
29.0

(1.5)
(1.5)
(0.9)
(1.6)

RN in the mixed lesion. Thus, once lesions are identiﬁed in
anatomic images, MTR serves to cleanly distinguish tumors
from RN.
2

H MRS

Semiheavy Water Natural Abundance (St. Louis
Region)
Titration experiments were performed on a series of water
phantoms of increasing deuterium concentration, added as D2O.
As noted earlier, because of rapid exchange, the actual deuterated
species present in these samples is principally HOD. For
simplicity, we express the composition of these phantoms in
terms of DHOD, in which DHOD represents 2H content above
natural-abundance levels found in local tap water. Figure 6 shows
2
H MR spectra acquired under quantitative pulse-and-collect
conditions. The spectra are characterized by high signal-to-noise
and symmetric lineshape. The linearity of detected signal
amplitude with 2H concentrations ranging from DHOD = 0 mM
to DHOD = 180 mM is illustrated in the inset plot in this ﬁgure.
From these data, the tap water natural-abundance 2H MR signal
amplitude corresponds to an HOD concentration of 16.35 mM.

Single Voxel (SPECIAL) Proﬁles
Figure 7 shows x-, y-, and z-direction 2H MRI proﬁles for a 4 × 4
× 4 mm3 SPECIAL voxel in the 10% D2O phantom. The nominal
selected voxel is shown as a black square in this ﬁgure, the proﬁle
direction as an orange arrow, and the RF surface coil as a yellow
oval. Symmetric, rectangular proﬁles are observed in the x and z
directions, perpendicular to the applied RF ﬁeld. The proﬁle in
the y-direction is less symmetric, reﬂecting the drop-off in RF
receptivity with increasing distance from the surface coil. The 2H
MR spectrum resulting from the selection of this voxel is shown
in Figure 7.
2

H MRS Metabolic Monitoring

2

H MRS is an emerging modality for measuring tumor
metabolism in tissues, and this study focused on its ability to
identify tumor and to distinguish tumor from RN. Figure 8
shows representative 2H MR spectra created by the summation

TABLE 2 | Statistical Comparison (p-values) of MR Parameter Values.

Tumor vs. Tumor in Mixed Model
RN vs. RN in Mixed Model
Tumor vs. RN
Tumor in Mixed vs. RN in Mixed Model

R1

R2

ADC

AUC

MTR

0.414
0.615
0.0007
<.0001

0.138
0.786
<.0001
<.0001

0.142
0.224
<.0001
0.0005

0.0348
0.362
0.326
0.0004

0.0134
0.0913
<.0001
<.0001

Bold values indicates statistical signiﬁcance at p < 0.05 level.
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FIGURE 5 | Contrast-enhanced (left) T1-weighted images, (middle) magnetization transfer ratio (MTR) parametric maps, and (right) H&E staining of: (top) pure tumor;
(middle) pure radiation necrosis; (bottom) mixed model, with tumor growing within a region of radiation necrosis. Red contours outline regions-of-interest of radiation
necrosis; yellow contours outline regions-of-interest of tumor. In the H&E, black arrows identify tumor and black arrow heads identify RN.

FIGURE 6 | Deuterium (2H = D) MR spectra and (inset) plot of signal amplitude (arbitrary units), for a series of HOD samples of increasing 2H concentration. 2H
concentration (DHOD) is expressed relative to that of tap water.
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FIGURE 7 | (left) 2H MRI proﬁles from a 4 × 4 × 4 mm3 SPECIAL voxel in a 10% D2O cylindrical phantom in the (top) Y, (middle) X, and (bottom) Z. The nominal
selected voxel is shown as a black square overlaid on a transverse slice (light gray) through the phantom, the proﬁle direction as an orange arrow, and the RF
surface coil as a yellow oval. (right) 2H MR spectrum resulting from selection of this 4 × 4 × 4 mm3 voxel.

recurrent tumor/RN (4). Investigators have attempted to resolve
this clinical problem by combining i) anatomic information from
CE T1W and T2W MRI; ii) microstructural information from
diffusion-weighted MRI; iii) functional information from perfusion
studies, including DCE or dynamic susceptibility contrast (DSC)
perfusion MRI; and iv) metabolic information from 1H MRS.
Although large meta-analyses of multiparametric MRI studies
designed to assess the differentiation of RN from recurrent
malignant tumors/RN showed that perfusion weighted imaging
metrics were relatively good at differentiation, signiﬁcant variability
in reported optimal thresholds and other limitations have
challenged widespread quantitative diagnosis (2). An important
shortcoming in the use of DSC-MRI is that its cerebral blood
volume-based tumor signature can be unavailable/unreliable in
some patients secondary to susceptibility artifacts from nearby
bone, calciﬁcation, or blood related to microhemorrhages, or due to
overlapping low CBV values in both conditions, i.e., RN vs
recurrent tumor/RN. Indeed, while CBV-based tumor signatures
have been shown to correlate histologically with image-guided
biopsies in a majority of specimens, up to 15% failed to distinguish
lesion identity secondary to technical problems (1), or were
inconclusive as a result of overlapping lower thresholds (20).
Similar indeterminacy is evident from 1H MRS studies (5–8) in
which various endogenous metabolite metrics show 70–80%
sensitivity and speciﬁcity in distinguishing RN vs. recurrent
tumor. For example, in a study of 23 patients, DSC combined

of the nine 10-min acquisitions during the administration of Glc.
Results of Bayesian spectral modeling (“decomposition”) are also
shown (Representative 2H MR spectra acquired from a single 30–
40 min time block are shown in Supplemental Data Figure S1).
The HOD and Glc 2H linewidths in the summed data were ~15–
20 and 20–25 Hz, respectively (0.2–0.3 ppm). Substantially
higher Lac and lower Glx signal amplitudes are seen for
tumors vs. RN. Figure 9 shows time-course plots for the
concentration of Lac and for the concentration ratio Glx : Lac
derived from these spectra, with Lac markedly higher (p <0.0001)
and Glx : Lac markedly lower (p <0.0001) in tumor vs. RN.
Compared to RN, the tumor almost exclusively converts Glc to
Lac in preference to oxidative metabolism (conversion to Glx).
Note the substantial dynamic range (~5×) of both Lac
concentration and Glx : Lac as 2H MRS-derived biomarkers for
distinguishing tumors and RN.

DISCUSSION
MR Indices of Tumor vs. RN
While most patients treated for malignant brain tumors are
followed during and after treatment with serial MR scans to
assess response to therapy and tumor stability, to date there is no
clinical MRI (or positron emission tomography (PET)) protocol
that consistently and accurately distinguishes pure RN from mixed
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FIGURE 8 | (top) 2H MR spectra created by summation of nine 10-min acquisitions during administration of Glc for (left) control, non-lesion-bearing mouse; (middle)
pure tumor; (right) pure radiation necrosis. (bottom) Results of Bayesian modeling of these spectra. Estimates and uncertainties of resonance frequencies,
amplitudes, and linewidths derived from decay-rate constants (R2*) for these spectra are summarized in Supplementary Data, Table S1.

was initially described as the Warburg effect (29, 30). It is a strategic
metabolic switch in glucose metabolism from predominantly
oxidative phosphorylation in normal cells to altered uptake and
metabolism of glucose in actively proliferating malignant cells.
Under this altered metabolism, glucose is avidly taken up by the
tumor cells and the majority is metabolized to lactate

with MRS was diagnostically successful in only 18 patients (72%)
(28). The above studies identify a continued need for improved,
widely available imaging biomarkers to distinguish pure RN from
recurrent tumors admixed in RN.
Reprogramming of glucose uptake and subsequent glycolysis, a
hallmark of malignant cancer cells and distinct from normal cells,

FIGURE 9 | Time-course plots (means ± SEM) for the concentration of (left) Lac and (middle) Glx, and (right) the concentration ratio Glx : Lac derived from a 90-min
series of 10-min acquisition spectra with n = 4 mice each condition (control, tumor-bearing, radiation necrosis). These time-course spectroscopy data were analyzed
using two-way ANOVA for repeated measurement, followed by post-hoc comparison of the least squares means (LSM) across groups. ANOVA2/LSM results are—Lac:
tumor vs. necrosis, p <0.0001; tumor vs. control, p <0.0001; necrosis vs. control, p = 0.7631; Glx: tumor vs. necrosis, p = 0.0671; tumor vs. control, p = 0.0004;
necrosis vs. control, p = 0.0685; Glx/Lac: tumor vs. necrosis, p <0.0001; tumor vs. control, p <0.0001; necrosis vs. control, p <0.0001.
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(fermentation) that is subsequently secreted from the cells. This
process is known as aerobic glycolysis as it occurs despite the
presence of sufﬁcient oxygen to support respiration. Aerobic
glycolysis is utilized by actively proliferating tumor cells having a
metabolic phenotype distinct from normal cells. Indeed, tumor
cells exhibit glycolytic ﬂux at rates up to 200 times those of normal
cells. Aerobic glycolysis generates adenosine triphosphate for
energy and increases the activity in the pentose phosphate
pathway. The potential utility of aerobic glycolysis as an
important metabolic bio-marker of tumor growth and
aggressiveness in high-grade gliomas was identiﬁed in patients
undergoing both [2-18F]FDG and [15O]-labeled CO, O2 and H2O
PET studies, with the calculation of a glycolytic index deﬁned by
linear regression of the cerebral metabolic rates of glucose and
oxygen (31). The identiﬁcation of elevated aerobic glycolysis as a
biomarker of tumor aggressiveness was correlated with a poor
prognosis in patients with high-grade gliomas (29).
An attractive alternative to PET, 2H MRS can quantify the
Warburg effect, thereby providing a tumor biomarker. 2H MR
takes advantage of rapid (quadrupolar dominated) spin-lattice
relaxation to efﬁciently time average signals. Scanning times for
2
H MRS are generally quite long, e.g., tens of minutes, and while
human 2H MR studies have been reported at 4 tesla (23) and are
certainly feasible at 3 tesla, signal-to-noise beneﬁts substantially
from high magnetic ﬁeld strength. 2H MRS, also referred to as
deuterium metabolic imaging DMI (23, 32–42), monitors the
metabolic products of administered deuterated substrates. 2H
MRS monitoring of the glycolytic conversion of Glc to Lac has
shown the tumor-signature Warburg effect in rat (23) and mouse
(40) glioblastoma models and clinically in human patients with
malignant gliomas (23). Inhibited glycolytic conversion of Glc to
Lac following chemotherapy (etoposide) was demonstrated by
2
H MRS in a mouse lymphoma tumor model (35).
Here, we determined the utility of various 1H MRI contrasts that
are readily/routinely available in the clinic for distinguishing
malignant gliomas from RN in three cohorts of mice: malignant
glioma; pure RN; and in the mixed lesion (malignant glioma
growing on an RN background). Our 1H MRI pipeline includes
parametric maps of R1, R2, ADC, DCEAUC, and MTR, and the
results in Table 1 clearly demonstrate the discriminating power of
these contrasts. Of particular interest and novelty is the success of
magnetization transfer (MT) contrast (Figure 4) for distinguishing
tumors and RN. Previously, MT has been proposed in a limited
number of studies. Van Zijl described a related approach, chemicalexchange saturation transfer (CEST), speciﬁcally, amide proton
exchange (APT), for distinguishing RN vs. tumor (43–45).
Recently, Mehrabian et al. (46), evaluated various CEST metrics in
a group of patients with prior stereotactic radiosurgery (SRS) for
metastatic brain disease and found that while APT did not
distinguish RN from progressive disease, various MTR-related
indices did. Acquiring quantitative CEST measures requires
considerable care in data acquisition and preprocessing. Our MTR
approach is simple, robust, and necessitates minimal data processing.
In concert with the 1H MRI pipeline, we also validated 2H MRS
as a modality for identifying tumors and distinguishing them from
RN. Using Glc as the administered metabolic substrate, we
demonstrated that Lac production is dramatically elevated and
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Glx production is signiﬁcantly reduced in tumor vs. control brain
tissue. These ﬁndings are consistent with markedly increased
aerobic glycolysis (i.e., Warburg effect, fermentation) and
reduced oxidative glucose metabolism (respiration) in tumors.
In contrast, Lac and Glx levels are only slightly changed in RN vs.
control, thus resembling more closely the oxidative glucose
metabolism observed in normal brain than in tumor.

Experimental Considerations
A useful attribute of 2H MR in vivo is that the natural abundance
of HOD 2H signaling provides an internal concentration reference.
Bowen et al. have assessed the stable isotope ratios of tap water in
the contiguous United States (20). 2H in tap water in the St. Louis,
Missouri region was found to vary between 145.9 and 148.3 ppm.
Given that water is 111.1 M in equivalent 1H, this translates to a
concentration range of 16.21–16.47 mM, with an average of 16.34
mM. Our standard addition MR titration results were strongly
conﬁrmatory, yielding an HOD concentration of 16.35 mM.
Several previous 2H MRS studies have used chemical shift
imaging (CSI) techniques to select a region of interest and generate
a grid of voxels to cover that region. In contrast, the 2H MRS
experiments described here were all single-voxel spectroscopy
measurements, SPECIAL with OVS. A challenge for CSI is the
signiﬁcant point-spread function associated with the method,
which introduces uncertainty as to exactly where the observed
signals originate. A challenge with the single-voxel spectroscopy
measurements described here is the use of a surface RF coil as both
transmitter and receiver, i.e., in the single-coil mode. Surface coils
are well understood to present an inhomogeneous RF magnetic
ﬁeld (B1) whose amplitude is strongest near the plane of the coil
but decreases substantially away from the coil plane. Surface coils
provide a sensitive volume nominally characterized by the coil
radius, with coils of smaller radii providing increased sensitivity,
but over a more limited volume. We chose a ~2-cm coil ID as a
trade-off between maximum sensitivity and full brain coverage as
qualitatively assessed by 2H CSI experiments with concentrated
D2O phantoms (data not shown).
To conﬁrm the 2H MRS performance of the SPECIAL pulse
sequence with surface-coil driven adiabatic 180° and 90° pulses, x,
y, and z projections of the single-voxel proﬁle were obtained with a
phantom (Figure 7). The voxel dimensions were well-deﬁned with
sharp boundaries. As expected, the proﬁle orthogonal to the coil
plane displays the well-known decreasing sensitivity with
increasing depth away from the coil. “Contaminating” signals
arising from regions outside the SPECIAL voxel are minimal.
(Recall that OVS was also employed in concert with the SPECIAL
pulse sequence). Following initial T1W 1H scans to deﬁne a given
lesion’s position and volume, the SPECIAL voxel position, size,
and orientation were nominally customized to ﬁt the lesion. Here,
the 6.5× difference in 1H vs. 2H resonance frequencies, 500 vs. 76.6
MHz, coupled with the 2.5× difference in coil dimensions, 5-cm
1
H volume coil vs. 2-cm 2H surface coil, advantageously led to near
zero coupling between the 1H and 2H channels. Thus, active or
geometrical decoupling of 1H vs. 2H RF circuits was not required, a
considerable experimental simpliﬁcation.
Finally, we note that the SPECIAL single-voxel 2 H
spectroscopy pulse sequence employed a short (4.27 ms) but
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ﬁnite TE, which could hamper the detection of lower abundance
2
H-labeled metabolites compared to 2H MRS pulse-and-acquire
approaches, as employed recently in normal rodent brain (36)
and GL261 mouse tumors (40).
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Summary
Employing mouse models of glioblastoma (GL261) and (Gamma
Knife-induced) radiation necrosis, we have shown that a 1H MRI
pipeline of commonly implemented protocols—maps of R1, R2,
ADC, MTR, and DCEAUC—provides substantial discriminatory
power to differentiate tumor from RN in both pure and mixedlesion cases. MTR scanning with long TR and minimal direct
saturation was particularly promising in this regard. Leveraging
the potential of MTR scanning as a complementary imaging
metric within a clinical MRI pipeline may improve diagnostic
capability in staging patients for recurrent brain tumors.
Additionally, the application of 2H MRS, in concert with the
infusion of Glc, provided substantial dynamic range in
distinguishing the two pure lesions, as tumors showed a strong
Warburg effect (aerobic glycolysis; fermentation) vs. oxidative
glucose metabolism (respiration) in RN and in control, normal
brain. These ﬁndings suggest a role for 2H metabolic imaging as a
possible means for substantially improving the discrimination
and staging of tumors vs. RN in the clinic.
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